Abstract
T-cell activation is dependent on signals delivered through the antigen-specific T-cell receptor and accessory receptors on T-cells. Integration of signals through this family of costimulatory and inhibitory receptors and their ligands regulates the balance between T-cell activation, tolerance, and immunopathology. Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals and exert a vital and diverse range of immunoregulatory roles in T-cell activation, tolerance, and immune-mediated tissue damage. In this review, we revisit current understanding of the immunoregulatory functions of PD-1 and its ligands and their involvement in immune-mediated diseases.
Keywords: Alzheimer's disease, autoimmunity, costimulation, HIV infection, immune tolerance, multiple sclerosis, PD-1, PD-L1, T-cell activation, immune system, microbial pathogens, antigens, antigenic peptide/major histocompatibility complex, costimulatory signals, phenotype
Current Molecular Medicine
Title: The PD-1/PD-L1 Pathway in Human Pathology
Volume: 12 Issue: 3
Author(s): M. Saresella, V. Rainone, N. M. Al-Daghri, M. Clerici and D. Trabattoni
Affiliation:
Keywords: Alzheimer's disease, autoimmunity, costimulation, HIV infection, immune tolerance, multiple sclerosis, PD-1, PD-L1, T-cell activation, immune system, microbial pathogens, antigens, antigenic peptide/major histocompatibility complex, costimulatory signals, phenotype
Abstract: T-cell activation is dependent on signals delivered through the antigen-specific T-cell receptor and accessory receptors on T-cells. Integration of signals through this family of costimulatory and inhibitory receptors and their ligands regulates the balance between T-cell activation, tolerance, and immunopathology. Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals and exert a vital and diverse range of immunoregulatory roles in T-cell activation, tolerance, and immune-mediated tissue damage. In this review, we revisit current understanding of the immunoregulatory functions of PD-1 and its ligands and their involvement in immune-mediated diseases.
Export Options
About this article
Cite this article as:
Saresella M., Rainone V., M. Al-Daghri N., Clerici M. and Trabattoni D., The PD-1/PD-L1 Pathway in Human Pathology, Current Molecular Medicine 2012; 12 (3) . https://dx.doi.org/10.2174/156652412799218903
DOI https://dx.doi.org/10.2174/156652412799218903 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
T Cell-based Therapies for Atherosclerosis
Current Pharmaceutical Design Patents Relating to the Application of Autologous Bone Marrow-Derived Mesenchymal Stromal Cell and Whole Marrow Transplantation for Neurodegenerative Diseases: A Review
Recent Patents on Regenerative Medicine Recent Patents on the Treatment of Type 1 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of Stem Cells in Muscular Dystrophies
Current Gene Therapy Cannabinoid Modulation of Neuroinflammatory Disorders
Current Neuropharmacology VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets MiR-19b Functions as a Potential Protector in Experimental Autoimmune Encephalomyelitis
Current Molecular Medicine Borna Disease Virus (BDV): Neuropharmacological Effects of a CNS Viral Infection
Current Neuropharmacology Isoprostanes as Biomarkers and Mediators of Oxidative Injury in Infant and Adult Central Nervous System Diseases
Current Neurovascular Research Interferon-beta Inhibits Th17 Cell Differentiation in Patients with Multiple Sclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Telomeres, Senescence and Longevity: The Role of Oxidative Stress and Antioxidants
Current Pharmacogenomics Role of Cytokines in Neurological Disorders
Current Medicinal Chemistry Estrogen Receptor Neurobiology and its Potential for Translation into Broad Spectrum Therapeutics for CNS Disorders
Current Molecular Pharmacology Role of Mitochondrial Heat-shock Proteins and Immunophilins in Neuro Degenerative Diseases
Current Drug Targets Evaluation of a Method Based on Coherence in Aqueous Systems and Resonance-Based Isotherapeutic Remedy in the Treatment of Chronic Psoriasis Vulgaris
Current Topics in Medicinal Chemistry From the Molecular Mechanism to Pre-clinical Results: Anti-epileptic Effects of Fingolimod
Current Neuropharmacology Directions for Enhancement of the Therapeutic Efficacy of Mesenchymal Stem Cells in Different Neurodegenerative and Cardiovascular Diseases: Current Status and Future Perspectives
Current Stem Cell Research & Therapy Migration and Function of Th17 Cells
Inflammation & Allergy - Drug Targets (Discontinued) BAFFling Autoimmune Disorders and Helicobacter pylori Disease: The Interplay between BAFF and the Th17 Response
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Molecular Targets to Promote Central Nervous System Regeneration
Current Neurovascular Research